医药：三代EGFR-TKI赛道竞争升级，同源康加入战局

Investment Rating - The industry investment rating is "Positive," indicating an expected overall return exceeding 5% above the CSI 300 index within the next six months [12]. Core Insights - The competition in the third-generation EGFR-TKI market is intensifying, with Tongyuan Kang entering the fray. Their drug TY-9591 has shown significant clinical benefits compared to Osimertinib in treating EGFR-mutant lung cancer with brain metastases [3][5]. - TY-9591 is a tyrosine kinase inhibitor (TKI) specifically developed for patients with EGFR-mutant lung cancer and brain metastases, demonstrating the ability to effectively cross the blood-brain barrier and irreversibly bind to EGFR mutations [4][6]. - The clinical trial results indicate that TY-9591 outperformed Osimertinib in terms of intracranial objective response rate (iORR), with significant statistical and clinical improvements across various patient subgroups [5][9]. Summary by Sections Industry Overview - The third-generation EGFR-TKI market is rapidly growing, with increasing patient numbers and a projected global sales figure for Osimertinib exceeding $6 billion by 2024 [7][9]. - There are currently seven third-generation EGFR-TKIs available in the domestic market, leading to heightened competition among manufacturers [10][11]. Company Insights - Tongyuan Kang's TY-9591 is the first and only drug in head-to-head clinical studies against Osimertinib to show significant superiority, with a trial involving 224 participants reflecting real-world mutation distribution [5][9]. - The safety profile of TY-9591 is favorable, with no new safety signals reported, and it utilizes deuterated technology to enhance brain penetration while reducing side effects [6][9].